Roche Partnership Will Advance Peptide Therapies Amid Obesity Risks
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 15 Analysts
Published
17 Aug 25
Updated
17 Aug 25
AnalystHighTarget's Fair Value
DKK 1,120.00
63.6% undervalued intrinsic discount17 Aug
DKK 408.00
1Y
-53.3%7D
19.6%